Silence Therapeutics plc
Silence Therapeutics plc (SLN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sln · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Silence Therapeutics plc (SLN) measures how much investors pay for each dollar of the company's trailing earnings. SLN's current PE ratio of N/A is calculated by dividing its stock price of $6.11 by its TTM earnings per share of -$1.80.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Silence Therapeutics plcYou SLN | $289M | N/A | — | -$1.80 |
 AC Immune S.A. ACIU | $223M | N/A | — | -$0.70 |
 Aldeyra Therapeutics, Inc. ALDX | $106M | N/A | — | -$0.56 |
 Amarin Corporation plc AMRN | $294M | N/A | — | -$1.87 |
 Alto Neuroscience, Inc. ANRO | $641M | N/A | — | -$2.19 |
 Capricor Therapeutics, Inc. CAPR | $1.2B | N/A | — | -$2.26 |
 Contineum Therapeutics, Inc. Class A Common Stock CTNM | $427M | N/A | — | -$2.17 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.88 | — | |
2024-12-31 FY2024 | — | $-2.94 | — | |
2023-12-31 FY2023 | — | $-3.50 | — | |
2022-12-31 FY2022 | — | $-3.82 | — | |
2021-12-31 FY2021 | — | $-1.33 | — | |
2020-12-31 FY2020 | — | $-1.19 | — | |
2019-12-31 FY2019 | — | $-0.78 | — | |
2018-12-31 FY2018 | — | $-0.79 | — | |
2017-12-31 FY2017 | — | $-0.07 | — | |
2016-12-31 FY2016 | — | $-0.36 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Silence Therapeutics plc (SLN) measures how much investors pay for each dollar of the company's trailing earnings. SLN's current PE ratio of N/A is calculated by dividing its stock price of $6.11 by its TTM earnings per share of -$1.80.
Frequently asked questions
SLN pe ratio · 6 questionsSLN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.11 and TTM EPS of -$1.80. Data sourced from Financial Modeling Prep via SLN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Silence Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08